Company

Bank

Analyst

Coverage

Opinion

Wk chg

1/4 cls

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)

Jefferies

Eun Yang

Price target

Buy

6%

$26.44

Leerink

Joseph Schwartz

Price target

Outperform

Yang raised her target to $29 from $24 after FDA approved Juxtapid lomitapide to treat patients with homozygous familial hypercholesterolemia (hoFH). Aegerion said it plans to launch the small molecule microsomal triglyceride transfer protein (MTP) inhibitor this month at an annual price of $200,000-$300,000 per patient. Yang expects peak sales of about $420M (see B12).

Schwartz raised his target to $30 from $25 on the Juxtapid approval. He expects peak product revenue of about $500M in 2027. Aegerion was off 3% for the week ended Dec. 28, 2012, when Yang and Schwartz issued their reports.